Zafgen Completes Phase 2 Clinical Trial Enrollment For Obesity Therapy Beloranib
News
Zafgen, a biotechnology company developing treatments for obesity and complex metabolic disorders, recently announced the completion of patient recruitment for ZAF-203, a Phase 2b clinical trial for beloranib, a therapy targeting patients ... Read more